Preliminary clinical results, showed a promising and durable response, with nilotinib in c-KIT metastatic melanoma patients showing mutation in exon 11, but nilotinib anti-tumor activity in melanoma patients with KIT amplification was not clear at this time (Table 3) [68]. The gene discussed is KIT; the disease is neoplasm.